decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
National_Coverage_Determinations_Manual / CARCINOEMBRYONIC_ANTIGEN
Subscribe or sign in to view the full article.
Article Overview
This policy article explains Medicare’s national coverage guidance for carcinoembryonic antigen (CEA) testing. It is relevant to oncology clinicians, coders, billing staff, and compliance teams who need to understand when the test is discussed as medically necessary, the general patient groups covered by the guidance, and the broad limits on repeat testing. The article also references related clinical guideline context and distinguishes between follow-up use, treatment monitoring, and limitations on testing frequency.
Why This Topic Matters
Understanding this coverage policy helps support correct interpretation of when CEA testing falls within Medicare’s national coverage framework and reduces denials or compliance problems related to inappropriate testing frequency or unsupported follow-up use.
Article Sections
-
Carcinoembryonic Antigen
Introduces the policy topic and provides general background on the laboratory marker and its role in oncology monitoring.
-
Indications
Summarizes the broad clinical scenarios discussed for coverage consideration, including follow-up and treatment-response monitoring in oncology settings.
-
Limitations
Describes the general constraints on repeat testing and the circumstances mentioned for more frequent review.
What You Will Learn
- The scope of Medicare coverage guidance for carcinoembryonic antigen testing
- The general oncology contexts discussed for follow-up and treatment monitoring
- The types of testing frequency limitations addressed in the policy
- The clinical and guideline context referenced by the article
Who Should Read This
- Medical coders
- Billing staff
- Oncology practices
- Compliance teams
- Utilization management professionals
- Payer policy researchers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com